Business Description
Seelos Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03832V3078
Description
Financial Strength
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.21 | |||||
Equity-to-Asset | -6.19 | |||||
Debt-to-Equity | -0.43 | |||||
Debt-to-EBITDA | -0.39 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -95.02 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 15.3 | |||||
3-Year EPS without NRI Growth Rate | 12.1 | |||||
3-Year FCF Growth Rate | 29.7 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 28.9 | |||||
14-Day RSI | 28.98 | |||||
6-1 Month Momentum % | -48.4 | |||||
12-1 Month Momentum % | -87.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.14 | |||||
Quick Ratio | 0.14 | |||||
Cash Ratio | 0.08 | |||||
Days Sales Outstanding | 249.36 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -75.3 | |||||
Shareholder Yield % | -320.11 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -4912.25 | |||||
Net Margin % | -4588.37 | |||||
FCF Margin % | -2947.42 | |||||
ROA % | -265.15 | |||||
ROIC % | -155.81 | |||||
ROC (Joel Greenblatt) % | -84472.6 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.57 | |||||
EV-to-EBIT | -0.43 | |||||
EV-to-EBITDA | -0.43 | |||||
EV-to-Revenue | 19.6 | |||||
EV-to-FCF | -0.66 | |||||
Earnings Yield (Greenblatt) % | -232.56 | |||||
FCF Yield % | -519.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Seelos Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.755 | ||
EPS (TTM) (€) | -12.763 | ||
Beta | -0.29 | ||
Volatility % | 116.91 | ||
14-Day RSI | 28.98 | ||
14-Day ATR (€) | 0.000288 | ||
20-Day SMA (€) | 2.655 | ||
12-1 Month Momentum % | -87.46 | ||
52-Week Range (€) | 2.643 - 43.29 | ||
Shares Outstanding (Mil) | 13.68 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Seelos Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Seelos Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Seelos Therapeutics Inc Frequently Asked Questions
What is Seelos Therapeutics Inc(STU:NXE)'s stock price today?
When is next earnings date of Seelos Therapeutics Inc(STU:NXE)?
Does Seelos Therapeutics Inc(STU:NXE) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |